AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30480729 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanadelumab 300 mg every 4 weeks (n=29)
Number of subjects: 125
Study 30480729 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanadelumab 300 mg every 2 weeks (n=27)
Number of subjects: 125
Study 30480729 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=41)
Number of subjects: 125
Study 25665812 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental insulin at bedtime for blood glucose (BG) >7.8 mmol/L
Number of subjects: 206
Study 25665812 — intervention group
Group type: COMPARATOR
Intervention: No supplemental insulin except for BG >19.4 mmol/L
Number of subjects: 206
Study 25665812 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental insulin at bedtime
Number of subjects: 206
Study 25665812 — intervention group
Group type: COMPARATOR
Intervention: No supplemental insulin
Number of subjects: 206
Study 24814472 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment (mindfulness-based therapy)
Number of subjects: 117
Study 24814472 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment (control group)
Number of subjects: 117
Study 19181486 — intervention group
Group type: EXPERIMENTAL
Intervention: prulifloxacin associated with ProstaMEV and FlogMEV
Number of subjects: 143
Study 19181486 — intervention group
Group type: COMPARATOR
Intervention: antibiotic therapy alone (prulifloxacin 600 mg daily for 14 days)
Number of subjects: 143
Study 15631092 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiao Gu San
Number of subjects: 60
Study 15631092 — intervention group
Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 60
Study 12133539 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) at a dosage of 1.0 - 1.5 g/d
Number of subjects: 46
Study 12133539 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (CYC) pulse therapy
Number of subjects: 46
Study 12133539 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 46
Study 9650871 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer dentifrice (0.3% triclosan, 2.0% copolymer, 0.243% sodium fluoride)
Number of subjects: 641
Study 9650871 — intervention group
Group type: COMPARATOR
Intervention: Control dentifrice (identical to test but without triclosan/copolymer)
Number of subjects: 641
Study 9650871 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 641
Study 9650871 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer dentifrice
Number of subjects: 641
Study 9650871 — intervention group
Group type: COMPARATOR
Intervention: Control dentifrice
Number of subjects: 641
Study 8703313 — intervention group
Group type: EXPERIMENTAL
Intervention: Broncho-Vaxom (B-V)
Number of subjects: 0
Study 8703313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2138973 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/GSD
Number of subjects: 11
Study 2138973 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/DG
Number of subjects: 11
Study 7372823 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha biofeedback training
Number of subjects: 66
Study 7372823 — intervention group
Group type: COMPARATOR
Intervention: Placebo biofeedback
Number of subjects: 66
Study 7372823 — intervention group
Group type: COMPARATOR
Intervention: No-treatment controls
Number of subjects: 66
Study 31840808 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quintiles of the Alternative Healthy Eating Index (aHEI)
Number of subjects: 9861
Study 31840808 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quintiles of the Dietary Approaches to Stop Hypertension (DASH)
Number of subjects: 9861
Study 31840808 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quintiles of the Mediterranean Diet Score (MDS)
Number of subjects: 9861
Study 31840808 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet quality scores (measured by aHEI, DASH, MDS)
Number of subjects: 9861
Study 30623248 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic formulation with amorphous form of BCS 2 class drug
Number of subjects: 0
Study 30623248 — intervention group
Group type: COMPARATOR
Intervention: Reference drug product with crystalline form
Number of subjects: 0
Study 27688475 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NC)
Number of subjects: 26
Study 27688475 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant endocrine therapy (NET)
Number of subjects: 26
Study 25039290 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care intervention
Number of subjects: 24
Study 25039290 — intervention group
Group type: EXPERIMENTAL
Intervention: Community children (never institutionalized)
Number of subjects: 24
Study 25039290 — intervention group
Group type: COMPARATOR
Intervention: Institutional care
Number of subjects: 24
Study 25039290 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 24
Study 25326691 — intervention group
Group type: COMPARATOR
Intervention: Placebo dopaminergic manipulation
Number of subjects: 0
Study 25326691 — intervention group
Group type: COMPARATOR
Intervention: Dopaminergic medication
Number of subjects: 0
Study 25326691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22978189 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Skill Assessment Program (MSAP) training
Number of subjects: 36
Study 20455982 — intervention group
Group type: EXPERIMENTAL
Intervention: T-VAC (duty-cycled, bipolar-unipolar RF generator with hexapolar tip)
Number of subjects: 60
Study 20455982 — intervention group
Group type: COMPARATOR
Intervention: ConvRF (conventional RF ablation with 8-mm tip catheter)
Number of subjects: 60
Study 20455982 — intervention group
Group type: EXPERIMENTAL
Intervention: T-VAC
Number of subjects: 60
Study 20455982 — intervention group
Group type: COMPARATOR
Intervention: ConvRF
Number of subjects: 60
Study 17547760 — intervention group
Group type: EXPERIMENTAL
Intervention: Active strategy (training module with administration of the guideline)
Number of subjects: 6395
Study 17547760 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive dissemination (administration of the guideline only)
Number of subjects: 6395
Study 17547760 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 6395
Study 15774254 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium paraaminobenzoate (4 x 3g/day for 12 months)
Number of subjects: 103
Study 15774254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 12356704 — intervention group
Group type: COMPARATOR
Intervention: Multidisciplinary training sessions on the active management of back pain delivered by a generic primary care educator or a clinical back pain expert.
Number of subjects: 0
Study 12356704 — intervention group
Group type: COMPARATOR
Intervention: Training delivered by a clinical back pain expert.
Number of subjects: 0
Study 9861607 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate supplementation (200 micrograms daily)
Number of subjects: 20
Study 9861607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9861607 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 20
Study 7836052 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 102
Study 7836052 — intervention group
Group type: COMPARATOR
Intervention: Cefonicid
Number of subjects: 102
Study 2192073 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse-dosed antibiotics administered in a single daily dose
Number of subjects: 79
Study 2192073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 212170 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with CCNU and hydroxyurea
Number of subjects: 346
Study 212170 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 346
Study 31335979 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin plus liraglutide 0.6 mg/day
Number of subjects: 70
Study 31335979 — intervention group
Group type: COMPARATOR
Intervention: Insulin alone
Number of subjects: 70
Study 28884856 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab trough level at week 26
Number of subjects: 0
Study 28884856 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab trough level of 5.0 μg/mL
Number of subjects: 0
Study 28884856 — intervention group
Group type: EXPERIMENTAL
Intervention: AAA development at week 26
Number of subjects: 0
Study 28884856 — intervention group
Group type: EXPERIMENTAL
Intervention: 6TGN level >222.5 p mol/8 ×108 RBCs
Number of subjects: 0
Study 25326519 — intervention group
Group type: EXPERIMENTAL
Intervention: CAG with autologous blood (Group I)
Number of subjects: 200
Study 25326519 — intervention group
Group type: COMPARATOR
Intervention: CAG with fibrin glue (Group II)
Number of subjects: 200
Study 23109001 — intervention group
Group type: EXPERIMENTAL
Intervention: Machined pure titanium (MPT)
Number of subjects: 6
Study 23109001 — intervention group
Group type: EXPERIMENTAL
Intervention: Cast pure titanium (CPT)
Number of subjects: 6
Study 23109001 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia (Zc)
Number of subjects: 6
Study 23109001 — intervention group
Group type: COMPARATOR
Intervention: Comparison of MPT and CPT
Number of subjects: 6
Study 23109001 — intervention group
Group type: COMPARATOR
Intervention: Comparison of all groups
Number of subjects: 6
Study 23109001 — intervention group
Group type: COMPARATOR
Intervention: Surface roughness correlation
Number of subjects: 6
Study 21641354 — intervention group
Group type: EXPERIMENTAL
Intervention: Transendocardial injection of autologous bone marrow mononuclear cells (ABMMNCs)
Number of subjects: 30
Study 21641354 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ABMMNC treatment)
Number of subjects: 30
Study 19254211 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine MR (two weeks prior to CABG and continued for 3 years)
Number of subjects: 306
Study 19254211 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine MR
Number of subjects: 306
Study 19254211 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy of IHD
Number of subjects: 306
Study 16442924 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (loading dose 300 mg followed by 75 mg/d for 8 weeks)
Number of subjects: 73
Study 16442924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 16442924 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel and Placebo
Number of subjects: 73
Study 15630287 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone supplements (40mg/d)
Number of subjects: 58
Study 15630287 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 58
Study 11332874 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.12 mg chlorphenamine maleate (0.4% nasal spray)
Number of subjects: 24
Study 11332874 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.24 mg chlorphenamine maleate (0.4% nasal spray)
Number of subjects: 24
Study 11332874 — intervention group
Group type: COMPARATOR
Intervention: 8 mg chlorphenamine maleate (tablets)
Number of subjects: 24
Study 9444443 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate aqueous nasal spray (MFNS) at 50, 100, or 200 micrograms once daily for 7 days
Number of subjects: 96
Study 9444443 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate aqueous nasal spray (MFNS) at 50, 100, or 200 micrograms once daily for 14 days
Number of subjects: 96
Study 9444443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 9444443 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate aqueous nasal spray (MFNS)
Number of subjects: 96
Study 9037289 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus injection of vasodilators
Number of subjects: 52
Study 9037289 — intervention group
Group type: COMPARATOR
Intervention: Slow injection of vasodilators
Number of subjects: 52
Study 9037289 — intervention group
Group type: COMPARATOR
Intervention: Tourniquet use
Number of subjects: 52
Study 9037289 — intervention group
Group type: COMPARATOR
Intervention: Bolus injection
Number of subjects: 52
Study 9037289 — intervention group
Group type: COMPARATOR
Intervention: Slow injection of low volume drug
Number of subjects: 52
Study 2667859 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose
Number of subjects: 14
Study 2667859 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral xylose
Number of subjects: 14
Study 2667859 — intervention group
Group type: COMPARATOR
Intervention: Control (normal subjects)
Number of subjects: 14
Study 2667859 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose and xylose
Number of subjects: 14
Study 822547 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg rifampicin daily for 12 weeks followed by once-weekly for 12 months
Number of subjects: 329
Study 822547 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg rifampicin once-weekly for 12, 18 or 24 months
Number of subjects: 329
Study 822547 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg rifampicin for longer than 1 year
Number of subjects: 329
Study 822547 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg rifampicin
Number of subjects: 329
Study 822547 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg rifampicin
Number of subjects: 329
Study 822547 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg rifampicin for 24 months
Number of subjects: 329
Study 28252473 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity functional exercise program (24 home-based sessions)
Number of subjects: 23
Study 28934137 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolysed soy protein formula
Number of subjects: 46
Study 28934137 — intervention group
Group type: EXPERIMENTAL
Intervention: Free amino acid formula
Number of subjects: 46
Study 26598474 — intervention group
Group type: EXPERIMENTAL
Intervention: MM+CBT
Number of subjects: 144
Study 26598474 — intervention group
Group type: COMPARATOR
Intervention: MM
Number of subjects: 144
Study 23855681 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 Gy in vitro radiation
Number of subjects: 0
Study 23855681 — intervention group
Group type: COMPARATOR
Intervention: 0 Gy in vitro radiation
Number of subjects: 0
Study 21925941 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 8 mg
Number of subjects: 552
Study 21925941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 552
Study 19380621 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 516
Study 19380621 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 516
Study 16683672 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gel with Ca(OH)2
Number of subjects: 3
Study 16683672 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gel
Number of subjects: 3
Study 16683672 — intervention group
Group type: COMPARATOR
Intervention: Ca(OH)2
Number of subjects: 3
Study 15459587 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine 60 microg
Number of subjects: 50
Study 15459587 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine 90 microg
Number of subjects: 50
Study 15459587 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine 120 microg
Number of subjects: 50
Study 15459587 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine 150 microg
Number of subjects: 50
Study 15459587 — intervention group
Group type: COMPARATOR
Intervention: Intravenous adenosine 140 microg/kg/min
Number of subjects: 50
Study 11737512 — intervention group
Group type: EXPERIMENTAL
Intervention: Periosonic instruments
Number of subjects: 11
Study 11737512 — intervention group
Group type: COMPARATOR
Intervention: Curettes
Number of subjects: 11
Study 9227247 — intervention group
Group type: EXPERIMENTAL
Intervention: Endorectal ultrasound (EUS)
Number of subjects: 62
Study 9227247 — intervention group
Group type: COMPARATOR
Intervention: Other techniques (serial CEA levels, digital examination, colonoscopy, pelvic CT)
Number of subjects: 62
Study 9227247 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage surgery
Number of subjects: 62
Study 9227247 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy or other palliative management
Number of subjects: 62
Study 9227247 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival after LR
Number of subjects: 62
Study 12959311 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibition with fosinopril, 20 mg day(‐1)
Number of subjects: 10
Study 12959311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2841818 — intervention group
Group type: EXPERIMENTAL
Intervention: estriol
Number of subjects: 60
Study 2841818 — intervention group
Group type: EXPERIMENTAL
Intervention: conjugated estrogens
Number of subjects: 60
Study 2841818 — intervention group
Group type: EXPERIMENTAL
Intervention: estrogen-gestagen sequential therapy
Number of subjects: 60
Study 2841818 — intervention group
Group type: EXPERIMENTAL
Intervention: extract from cimicifuga racemosa
Number of subjects: 60
Study 2841818 — intervention group
Group type: COMPARATOR
Intervention: Control group (all therapies)
Number of subjects: 60
Study 30777123 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 86
Study 30777123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 27671460 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2
Number of subjects: 36
Study 27671460 — intervention group
Group type: COMPARATOR
Intervention: ICM
Number of subjects: 36
Study 26108222 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lysergic acid diethylamide (200 μg)
Number of subjects: 16
Study 24074332 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination budesonide/formoterol inhaler according to a single inhaler regimen (SMART)
Number of subjects: 303
Study 20461422 — intervention group
Group type: COMPARATOR
Intervention: Alendronate (5 mg/day)
Number of subjects: 1780
Study 20461422 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol (1 μg/day) + Alendronate (5 mg/day)
Number of subjects: 1780
Study 18300904 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-level, unilateral, lumbar microdiscectomy
Number of subjects: 168
Study 18300904 — intervention group
Group type: EXPERIMENTAL
Intervention: Facet joint angle less than 35 degrees
Number of subjects: 168
Study 18300904 — intervention group
Group type: EXPERIMENTAL
Intervention: Facet joint angle greater than 35 degrees
Number of subjects: 168
Study 16538542 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense sequential chemotherapy (3 cycles of epirubicin 110 mg/m2 followed by 3 cycles of paclitaxel 250 mg/m2 followed by 3 cycles of intensified CMF)
Number of subjects: 595
Study 16538542 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy (4 cycles of epirubicin followed by 4 cycles of CMF)
Number of subjects: 595
Study 16538542 — intervention group
Group type: EXPERIMENTAL
Intervention: HER-2 overexpression
Number of subjects: 595
Study 16538542 — intervention group
Group type: EXPERIMENTAL
Intervention: High expression of VEGF
Number of subjects: 595
Study 14499022 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual healing treatment (3 weekly sessions lasting approximately 30 minutes each)
Number of subjects: 68
Study 14499022 — intervention group
Group type: COMPARATOR
Intervention: Normal care (no spiritual healing)
Number of subjects: 68
Study 10920469 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (mean daily dose, 2.2 +/- 0.7 mg/d)
Number of subjects: 36
Study 10920469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 10920469 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label risperidone addition
Number of subjects: 36
Study 8612028 — intervention group
Group type: EXPERIMENTAL
Intervention: SSZ (2g/day) and pulses of MP (5 mg/kg)
Number of subjects: 38
Study 8612028 — intervention group
Group type: COMPARATOR
Intervention: SSZ (2g/day) and pulses of saline (SA)
Number of subjects: 38
Study 1420795 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured talk lasting ten minutes and supplied with a 'Guide to Giving up Smoking' (n = 48)
Number of subjects: 102
Study 1420795 — intervention group
Group type: COMPARATOR
Intervention: Advised to give up the habit (Control group, n = 50)
Number of subjects: 102
Study 6692287 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg tamoxifen daily
Number of subjects: 31
Study 6692287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 30718802 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy for 2 hours
Number of subjects: 94
Study 30718802 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy for 7 hours
Number of subjects: 94
Study 29943719 — intervention group
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine (5 doses of 2.7 × 10^5 PfSPZ at 0, 4, 8, 12, and 20 weeks)
Number of subjects: 20
Study 29943719 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 20
Study 27338955 — intervention group
Group type: EXPERIMENTAL
Intervention: TRABC in addition to conventional Western treatment
Number of subjects: 240
Study 27338955 — intervention group
Group type: COMPARATOR
Intervention: Conventional Western treatment
Number of subjects: 240
Study 27338955 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 240
Study 24993276 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with femoral nerve block
Number of subjects: 0
Study 24993276 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia alone
Number of subjects: 0
Study 22381530 — intervention group
Group type: EXPERIMENTAL
Intervention: i-SCAN contrast/surface enhancement (CE/SE) mode (i-SCAN1 group; n = 115)
Number of subjects: 389
Study 22381530 — intervention group
Group type: EXPERIMENTAL
Intervention: i-SCAN CE/SE/tone enhancement-colorectal mode (i-SCAN2 group; n = 118)
Number of subjects: 389
Study 22381530 — intervention group
Group type: COMPARATOR
Intervention: Conventional high-definition white light (HDWL group; n = 119)
Number of subjects: 389
Study 20191783 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular blockade (NMB)
Number of subjects: 102
Study 20191783 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to eligibility for PACU discharge
Number of subjects: 102
Study 20191783 — intervention group
Group type: EXPERIMENTAL
Intervention: Requirement for airway support
Number of subjects: 102